# Hygea Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hygea-medical-technology-co

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.hygeamed.com
- Total disclosed funding: $120M
- Latest round: Series D (Feb 15, 2023)
- Investors on record: 17

## About

Based in Beijing, China and established in 2010, Hygea Medical Technology Co. Ltd. is a medical company that focuses on minimally invasive interventional tumors and cryogenic medicine. In 2019, the company raised approximately RMB 200 million in Series B funding from CCB International Asset Management, Kunying Capital and Shuncheng Equity Investment Fund.

The company engages in the research and development of tumor minimally invasive treatment equipment. Its main product called Kangbo Dao. Kangbo Dao destroys the target tissue through thermal stress and high temperature generated by switching between cold and heat.

## Funding rounds

- Series D, Feb 15, 2023, $15M — In Capital, Gaorong Ventures, Qiandao Investment Fund Management, Huajin Lingchuang Fund Management, Banyan Pacific Capital, MeiHong Fund
- Series C, Jul 13, 2021 — Gaorong Ventures
- Series C, Apr 26, 2021, $77M — Shanghai Jianyi Private Equity Fund Management, China Growth Capital, SenseTime Group Limited, China Reform Holdings, BioTrack Capital
- Series B, Dec 6, 2019, $28M — CCB International Asset Management, Shuncheng Equity Investment Fund, Kunying Capital
- Series A, Dec 13, 2018 — Fujian Venture
- Series A, Aug 4, 2017 — Zhongguancun Development Group, Chuchang Fund

## Investors

- Zhongguancun Development Group — Series A
- Chuchang Fund (https://capitalatlas.ai/funds/chuchang-fund) — Series A
- Fujian Venture (https://capitalatlas.ai/funds/fujian-venture) — Series A
- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series B
- Shuncheng Equity Investment Fund (https://capitalatlas.ai/funds/shuncheng-equity-investment-fund) — Series B
- Kunying Capital — Series B
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series C
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series C
- SenseTime Group Limited — Series C
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series C
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series C
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series C, Series D
- In Capital — Series D
- Qiandao Investment Fund Management (https://capitalatlas.ai/funds/qiandao-investment-fund-management) — Series D
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series D
- Banyan Pacific Capital — Series D
- MeiHong Fund — Series D